China's drug regulator granted Yifan Pharmaceutical (SHE:002019) subsidiary Hefei Yifan Biopharmaceutical marketing and production approval for its difenafine acetate injection.
The drug helps treat moderate to severe pruritus or itching in hemodialysis patients, according to a Saturday filing with the Shenzhen bourse.